USMLE/COMLEX 3 - Hypertension Pathophysiology

Here are key facts for USMLE Step 3 & COMLEX-USA Level 3 from the Blood Pressure Regulation and Hypertension tutorial, as well as points of interest at the end of this document that are not directly addressed in this tutorial but should help you prepare for the boards. See the tutorial notes for further details and relevant links.

• --

1. Primary determinants of mean arterial pressure:

• Cardiac output: product of heart rate and stroke volume
• Total peripheral resistance: primarily determined by vasoconstriction of small arteries and arterioles
• Application to management: therapies target one or both components

2. Preload determinants and management implications:

• Blood volume significantly contributes to preload
• Sodium and water retention in kidneys affects blood volume
• Clinical implication: diuretics and sodium restriction reduce preload

3. Vasoconstriction mechanisms and therapeutic targets:

• Small arteries and arterioles are primary resistance vessels
• Vasoconstriction mediators: angiotensin II, norepinephrine, antidiuretic hormone, endothelin
• Management approach: vasodilators target these specific pathways

1. Posterior pituitary and ADH:

• Vasopressin functions as vasoconstrictor
• Increases sodium and water retention
• Management implications: ADH antagonists (vaptans) in specific scenarios

2. Renin-Angiotensin-Aldosterone System:

• Angiotensin II: direct vasoconstriction and sodium/water retention
• Indirect effects: stimulates norepinephrine, ADH, and aldosterone
• Multiple antihypertensive classes target this system: ACE inhibitors, ARBs, direct renin inhibitors

3. Adrenal cortex and aldosterone:

• Similar effects to ADH on sodium/water retention
• Management target: mineralocorticoid receptor antagonists

4. Sympathetic nervous system and norepinephrine:

• Increases heart rate, contractility, and vasoconstriction
• Management targets: beta-blockers, alpha-blockers

1. Classification and differentiation:

• Hypertensive urgency: BP >180/120 mmHg without end-organ damage
• Hypertensive emergency: BP >180/120 mmHg with end-organ damage
• Management differs based on this critical distinction

2. Clinical presentation:

• Severe headache, confusion, impaired vision
• Chest pain, shortness of breath
• Nausea/vomiting, anxiety, seizures
• These symptoms suggest end-organ damage requiring immediate intervention

• --

1. Endogenous vasodilators:

• Nitric oxide, prostaglandins, histamine, bradykinin
• Therapeutic implications: medications that enhance these pathways
• Bradykinin is broken down by angiotensin II, contributing to ACE inhibitor effects

2. Angiotensin II and bradykinin relationship:

• ACE inhibitors reduce angiotensin II and increase bradykinin
• This dual effect explains both efficacy and side effects (cough, angioedema)
• Understanding explains why ARBs have similar efficacy without bradykinin-related side effects

3. Vascular remodeling implications:

• Chronic hypertension leads to structural changes
• Altered balance of endothelin (increased) and nitric oxide (decreased)
• Therapeutic challenge: may require multiple agents and longer treatment course

1. Salt sensitivity evaluation:

• Some patients develop hypertension due to sodium retention
• Clinical approach: trial of sodium restriction and diuretic therapy
• Response indicates underlying pathophysiology

2. Secondary hypertension with aldosterone excess:

• Presents with elevated blood volume and preload
• Clinical indicators: hypokalemia, metabolic alkalosis
• Diagnostic approach: aldosterone-renin ratio measurement

3. Environmental and genetic factors:

• Multiple factors affect various components of blood pressure regulation
• Family history assessment is crucial
• Tailored approach based on identified factors

• --

Below is information not explicitly contained within the tutorial but important for USMLE Step 3 & COMLEX Level 3. 1. Comprehensive treatment approach:

• Initial evaluation of predominant mechanism (volume vs. resistance)
• Stepwise medication selection based on underlying pathophysiology
• Monitoring parameters beyond blood pressure (electrolytes, renal function)

2. Resistant hypertension workup:

• Systematic evaluation for secondary causes
• Medication adherence assessment
• Consideration of interfering substances (NSAIDs, stimulants)
• Therapeutic drug monitoring when appropriate

3. Special population management:

• Pregnancy: risk-benefit considerations, safe medication selection
• Elderly: focus on systolic hypertension, risk of orthostatic hypotension
• Comorbidities: diabetes, CKD, heart failure - tailored approaches

1. Implementation of clinical guidelines:

• Evidence-based target selection for different populations
• Risk stratification approaches
• Quality measures and performance improvement

2. Systems-based practice:

• Team-based care models for hypertension management
• Care coordination for complex patients
• Population health approaches to blood pressure control

3. Clinical decision support:

• Electronic health record tools for hypertension management
• Remote monitoring integration
• Adherence support strategies